/CERE

CERE Stock - Cerevel Therapeutics Holdings, Inc.

Q: What is the analyst price target for CERE?

Analyst price target information is not currently available for CERE.

Q: What is CERE's market cap?

Market capitalization information is not currently available for CERE.

Healthcare|Biotechnology|NASDAQ

$44.96+0.74%

+$0.33 (+0.74%) • Jul 31

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+-25.5%upside

Target: $33.50

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for CERE

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2019

FY2020

FY2021

FY2022

FY2023

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.41

52W High$44.99

52W Low$19.59

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2023	FY2022	FY2021	FY2020	FY2019
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	$-5,627,000	$-4,903,000	$-2,731,000	$-397,000	N/A
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$-447,265,000	$-367,848,000	$-220,098,000	$-149,116,000	$-83,463,000
Net Income	$-432,842,000	$-351,511,000	$-222,446,000	$-152,142,000	$-128,389,000
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$-2.67	$-2.32	$-1.63	$-1.29	$-1.01

Company Overview

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat acute anxiety. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; CVL-936, a selective dopamine D3-preferring antagonist, which is in Phase I clinical trial for the treatment of substance use disorder; CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder; and CVL-047, selective PDE4 inhibitor for the treatment of major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and an LRRK2 inhibitor program to address disease progression in Parkinson's. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

40%

Hold / Neutral

60%

Sell / Underperform

Analyst Consensus🔴 Bearish

4 Bullish6 Neutral/Bearish

Price Targets

$33

Average Target

↓ 25.9% Downside

Now

$22

Low

$33

Average

$45

High

Based on 13 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
December 8th 2023	TD Cowen	Downgrade	Market Perform	$45
November 20th 2023	JP Morgan	Resumed	Neutral	$25
September 28th 2023	Piper Sandler	Initiation	Overweight	$33
August 3rd 2023	BofA Securities	Downgrade	Neutral	$31← $36
May 4th 2023	Wells Fargo	Upgrade	Overweight	$30
April 10th 2023	TD Cowen	Initiation	Outperform	-
March 17th 2023	JP Morgan	Downgrade	Neutral	$29← $40
March 16th 2023	Berenberg	Resumed	Hold	$22
February 23rd 2023	Wells Fargo	Downgrade	Equal Weight	$30← $38
November 1st 2022	Loop Capital	Initiation	Buy	$40
October 20th 2022	BofA Securities	Initiation	Buy	$39
September 29th 2022	Cantor Fitzgerald	Initiation	Overweight	$41
September 26th 2022	Wells Fargo	Initiation	Overweight	$38
September 13th 2022	Evercore ISI	Initiation	Outperform	-
July 7th 2022	Mizuho	Initiation	Neutral	$30

Earnings History & Surprises

CERE

Beat Rate

40%

Last 15 quarters

Avg Surprise

-1.5%

EPS vs Estimate

Beats / Misses

6/8

1 met exactly

Latest EPS

$-0.63

Q3 2024

EPS Surprise History

Q4 22

-6.5%

$-0.66vs$-0.62

Q1 23

+7.8%

$-0.59vs$-0.64

Q2 23

0.0%

$-0.67vs$-0.67

Q3 23

+3.1%

$-0.63vs$-0.65

Q4 23

+3.2%

$-0.61vs$-0.63

Q2 24

-19.7%

$-0.73vs$-0.61

Q2 24

-10.9%

$-0.73vs$-0.66

Q3 24

-3.3%

$-0.63vs$-0.61

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q3 2024	Aug 7, 2024	$-0.61	$-0.63	-3.3%	✗ MISS
Q2 2024	May 8, 2024	$-0.66	$-0.73	-10.9%	✗ MISS
Q2 2024	May 1, 2024	$-0.61	$-0.73	-19.7%	✗ MISS
Q4 2023	Nov 1, 2023	$-0.63	$-0.61	+3.2%	✓ BEAT
Q3 2023	Aug 2, 2023	$-0.65	$-0.63	+3.1%	✓ BEAT
Q2 2023	May 3, 2023	$-0.67	$-0.67	0.0%	= MET
Q1 2023	Feb 22, 2023	$-0.64	$-0.59	+7.8%	✓ BEAT
Q4 2022	Nov 8, 2022	$-0.62	$-0.66	-6.5%	✗ MISS
Q3 2022	Aug 1, 2022	$-0.50	$-0.61	-22.0%	✗ MISS
Q2 2022	May 10, 2022	$-0.44	$-0.46	-4.5%	✗ MISS
Q1 2022	Mar 1, 2022	$-0.41	$-0.40	+2.4%	✓ BEAT
Q4 2021	Nov 10, 2021	$-0.40	$-0.43	-7.5%	✗ MISS
Q3 2021	Aug 11, 2021	$-0.41	$-0.42	-2.4%	✗ MISS
Q2 2021	May 17, 2021	$-0.45	$-0.40	+11.1%	✓ BEAT
Q1 2021	Mar 24, 2021	$-0.37	$-0.27	+27.0%	✓ BEAT
Q4 2020	Nov 16, 2020	—	$-0.31	—	—
Q4 2020	Oct 7, 2020	—	$-0.21	—	—
Q1 2020	Mar 31, 2020	—	$-0.42	—	—
Q4 2019	Dec 31, 2019	—	$-0.35	—	—
Q3 2019	Sep 30, 2019	—	$-0.50	—	—

Frequently Asked Questions about CERE

What is CERE's current stock price?

Cerevel Therapeutics Holdings, Inc. (CERE) is currently trading at $44.96 per share. The stock has moved +0.74% today.

What is the analyst price target for CERE?

The average analyst price target for CERE is $33.50, based on 1 analyst.

What sector is Cerevel Therapeutics Holdings, Inc. in?

Cerevel Therapeutics Holdings, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is CERE's market cap?

Cerevel Therapeutics Holdings, Inc. has a market capitalization of $8.19 billion, making it a mid-cap company.

Does CERE pay dividends?

No, Cerevel Therapeutics Holdings, Inc. does not currently pay a dividend to shareholders.